NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel immunomedicines and cures for cancer and other immune-related diseases through scientific innovation, patient needs, and organizational excellence. They focus on patients who do not respond to current therapies and develop therapies addressing immune evasion and suppression in the tumor microenvironment. The company leverages proprietary FIND-IO™ technology to identify novel immune targets and develop next-generation immunotherapies.
Industries
Nr. of Employees
medium (51-250)
NextCure, Inc.
9000 Virginia Manor Road, Suite 200, Beltsville, MD 20705, USA
Patents
Products
Functional immune discovery platform (FIND-IO)
A functional discovery platform that screens primary human immune cells and established cell lines to identify cell-surface interactions and immunomodulatory targets for development of immunomedicines.
Clinical-stage monoclonal antibody programs targeting novel immunomodulatory targets
Clinical-stage immunomedicine programs consisting of monoclonal antibodies directed against novel immunoregulatory targets identified through functional discovery, advanced into first-in-human Phase 1/2 studies.
Functional immune discovery platform (FIND-IO)
A functional discovery platform that screens primary human immune cells and established cell lines to identify cell-surface interactions and immunomodulatory targets for development of immunomedicines.
Clinical-stage monoclonal antibody programs targeting novel immunomodulatory targets
Clinical-stage immunomedicine programs consisting of monoclonal antibodies directed against novel immunoregulatory targets identified through functional discovery, advanced into first-in-human Phase 1/2 studies.
Services
Joint research collaborations with academic institutions for discovery, target validation and publication to support translational programs.
Joint research collaborations with academic institutions for discovery, target validation and publication to support translational programs.
Expertise Areas
- Functional target discovery in immuno-oncology
- Translational development from target discovery to clinic
- Monoclonal antibody development
- Antibody-drug conjugate strategies
Key Technologies
- Functional immune-pathway screening platform
- Genome-scale T-cell activity arrays
- Primary immune cell and cell-line-based functional assays
- Monoclonal antibody therapeutics
News & Updates
A research paper describing Siglec-15 (S15) as a new target for immunotherapy, published in Nature Medicine, led by Prof. Lieping Chen from Yale University in collaboration with NextCure.
A research paper describing Siglec-15 (S15) as a new target for immunotherapy, published in Nature Medicine, led by Prof. Lieping Chen from Yale University in collaboration with NextCure.
A research paper describing Siglec-15 (S15) as a new target for immunotherapy, published in Nature Medicine, led by Prof. Lieping Chen from Yale University in collaboration with NextCure.
A research paper describing Siglec-15 (S15) as a new target for immunotherapy, published in Nature Medicine, led by Prof. Lieping Chen from Yale University in collaboration with NextCure.